The Latin America, Middle East and Africa Pain Patch Market should witness market growth of 6.9% CAGR during the forecast period (2023-2029).
The market for pain patches is expected to grow profitably as more people turn to pain patches to deal with the discomfort brought on by a variety of medical ailments. In addition, the pain patch market is booming as a result of the rising incidence of chronic illnesses and the growing elderly population. Also, the expansion of government programs to improve healthcare facilities, concentrate on research, and increase financing for research support market growth.
Aged people are more vulnerable to chronic pain-producing conditions such as joint problems, neuropathic pain, and others. As the number of aged people is growing, the market is also anticipated to grow significantly. In addition, a rise in the frequency of work- and sports-related trauma injuries, such as sprains, strains, fractures, tendinitis, and back injuries, is anticipated to spur market expansion. There is an increase in the occurrence of low back pain cases in adults, which further fuels market expansion.
Israel's population is aging more quickly than average. The number of persons 65 and older has increased 18-fold since 1950. The overall population of Israel is projected to reach 12.1 million by 2035, with seniors making up about 14% of that total population or 1.9 million people. Ages 65 and older made up just 4% of the population in 1948, the year the State of Israel was founded. Throughout the years, this population has grown steadily. Given an increasing life expectancy, it has climbed by 1% annually since 1995 and is predicted to continue to rise. The demand for pain patches is expected to surge with the growing number of older age population in the region.
The Brazil market dominated the LAMEA Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $135.6 million by 2029. The Argentina market is exhibiting a CAGR of 7.4% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 6.6% during (2023-2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
The market for pain patches is expected to grow profitably as more people turn to pain patches to deal with the discomfort brought on by a variety of medical ailments. In addition, the pain patch market is booming as a result of the rising incidence of chronic illnesses and the growing elderly population. Also, the expansion of government programs to improve healthcare facilities, concentrate on research, and increase financing for research support market growth.
Aged people are more vulnerable to chronic pain-producing conditions such as joint problems, neuropathic pain, and others. As the number of aged people is growing, the market is also anticipated to grow significantly. In addition, a rise in the frequency of work- and sports-related trauma injuries, such as sprains, strains, fractures, tendinitis, and back injuries, is anticipated to spur market expansion. There is an increase in the occurrence of low back pain cases in adults, which further fuels market expansion.
Israel's population is aging more quickly than average. The number of persons 65 and older has increased 18-fold since 1950. The overall population of Israel is projected to reach 12.1 million by 2035, with seniors making up about 14% of that total population or 1.9 million people. Ages 65 and older made up just 4% of the population in 1948, the year the State of Israel was founded. Throughout the years, this population has grown steadily. Given an increasing life expectancy, it has climbed by 1% annually since 1995 and is predicted to continue to rise. The demand for pain patches is expected to surge with the growing number of older age population in the region.
The Brazil market dominated the LAMEA Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $135.6 million by 2029. The Argentina market is exhibiting a CAGR of 7.4% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 6.6% during (2023-2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
Scope of the Study
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Type
- Prescription Medicines
- OTC Medicines
By Product Type
- Non-Opioid Patches
- Nonsteroidal Anti-Inflammatory Drugs
- Methyl Salicylate
- Lidocaine
- Others
- Opioid Patches
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- NEXGEL, Inc.
- Viatris, Inc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Grunenthal GmbH
- Sorrento Therapeutics, Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Endo International PLC
- Purdue Pharma L.P.
- Amneal Pharmaceuticals, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Pain Patch Market, by Distribution Channel
1.4.2 LAMEA Pain Patch Market, by Type
1.4.3 LAMEA Pain Patch Market, by Product Type
1.4.4 LAMEA Pain Patch Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Pain Patch Market by Distribution Channel
3.1 LAMEA Drug Stores & Retail Pharmacies Market by Country
3.2 LAMEA Hospital Pharmacies Market by Country
3.3 LAMEA Online Providers Market by Country
Chapter 4. LAMEA Pain Patch Market by Type
4.1 LAMEA Prescription Medicines Market by Country
4.2 LAMEA OTC Medicines Market by Country
Chapter 5. LAMEA Pain Patch Market by Product Type
5.1 LAMEA Non-Opioid Patches Market by Country
5.2 LAMEA Pain Patch Market by Non-Opioid Patches Type
5.2.1 LAMEA Nonsteroidal Anti-Inflammatory Drugs Market by Country
5.2.2 LAMEA Methyl Salicylate Market by Country
5.2.3 LAMEA Lidocaine Market by Country
5.2.4 LAMEA Others Market by Country
5.3 LAMEA Opioid Patches Market by Country
Chapter 6. LAMEA Pain Patch Market by Country
6.1 Brazil Pain Patch Market
6.1.1 Brazil Pain Patch Market by Distribution Channel
6.1.2 Brazil Pain Patch Market by Type
6.1.3 Brazil Pain Patch Market by Product Type
6.1.3.1 Brazil Pain Patch Market by Non-Opioid Patches Type
6.2 Argentina Pain Patch Market
6.2.1 Argentina Pain Patch Market by Distribution Channel
6.2.2 Argentina Pain Patch Market by Type
6.2.3 Argentina Pain Patch Market by Product Type
6.2.3.1 Argentina Pain Patch Market by Non-Opioid Patches Type
6.3 UAE Pain Patch Market
6.3.1 UAE Pain Patch Market by Distribution Channel
6.3.2 UAE Pain Patch Market by Type
6.3.3 UAE Pain Patch Market by Product Type
6.3.3.1 UAE Pain Patch Market by Non-Opioid Patches Type
6.4 Saudi Arabia Pain Patch Market
6.4.1 Saudi Arabia Pain Patch Market by Distribution Channel
6.4.2 Saudi Arabia Pain Patch Market by Type
6.4.3 Saudi Arabia Pain Patch Market by Product Type
6.4.3.1 Saudi Arabia Pain Patch Market by Non-Opioid Patches Type
6.5 South Africa Pain Patch Market
6.5.1 South Africa Pain Patch Market by Distribution Channel
6.5.2 South Africa Pain Patch Market by Type
6.5.3 South Africa Pain Patch Market by Product Type
6.5.3.1 South Africa Pain Patch Market by Non-Opioid Patches Type
6.6 Nigeria Pain Patch Market
6.6.1 Nigeria Pain Patch Market by Distribution Channel
6.6.2 Nigeria Pain Patch Market by Type
6.6.3 Nigeria Pain Patch Market by Product Type
6.6.3.1 Nigeria Pain Patch Market by Non-Opioid Patches Type
6.7 Rest of LAMEA Pain Patch Market
6.7.1 Rest of LAMEA Pain Patch Market by Distribution Channel
6.7.2 Rest of LAMEA Pain Patch Market by Type
6.7.3 Rest of LAMEA Pain Patch Market by Product Type
6.7.3.1 Rest of LAMEA Pain Patch Market by Non-Opioid Patches Type
Chapter 7. Company Profiles
7.1 NEXGEL, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.2 Viatris, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental Analysis
7.2.4 Research & Development Expense
7.3 Johnson & Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 SWOT Analysis
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Grünenthal GmbH
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trials:
7.6 Sorrento Therapeutics, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental Analysis
7.6.4 Research & Development Expenses
7.7 Hisamitsu Pharmaceutical Co. Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Recent strategies and developments:
7.7.3.1 Product Launches and Product Expansions:
7.8 Endo International PLC
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expense
7.9 Purdue Pharma L.P.
7.9.1 Company Overview
7.10. Amneal Pharmaceuticals, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations, and Agreements:
7.10.5.1 Approvals & Trials:
Companies Mentioned
- NEXGEL, Inc.
- Viatris, Inc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Grunenthal GmbH
- Sorrento Therapeutics, Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Endo International PLC
- Purdue Pharma L.P.
- Amneal Pharmaceuticals, Inc.
Methodology
LOADING...
